keyword
MENU ▼
Read by QxMD icon Read
search

metastatic eving sarcoma

keyword
https://www.readbyqxmd.com/read/28852958/clinical-benefit-of-antiangiogenic-therapy-in-advanced-and-metastatic-chondrosarcoma
#1
Robin L Jones, Daniela Katz, Elizabeth T Loggers, Darin Davidson, Eve T Rodler, Seth M Pollack
Chondrosarcoma is the most common bone sarcoma in adults. Conventional chondrosarcoma, the commonest histological subtype, is largely resistant to anthracycline-based chemotherapy. There have been anecdotal reports of durable clinical benefit with antiangiogenic agents in this disease. A retrospective search of patients treated at three sarcoma referral centers was performed to identify patients with advanced chondrosarcoma treated with antiangiogenic agents. The aim of this study was to evaluate the efficacy and safety of antiangiogenic agents in advanced chondrosarcoma...
August 29, 2017: Medical Oncology
https://www.readbyqxmd.com/read/25257906/analysis-of-clinical-prognostic-factors-for-adult-patients-with-head-and-neck-sarcomas
#2
Amy E Chang, Xiaoyu Chai, Seth M Pollack, Elizabeth Loggers, Eve Rodler, Jasjit Dillon, Upendra Parvathaneni, Kris S Moe, Neal Futran, Robin L Jones
OBJECTIVE: To evaluate the treatment, outcome, and prognostic factors in patients with head and neck sarcomas treated in an academic medical center. STUDY DESIGN: Case series. SETTING: Academic medical center. SUBJECTS AND METHODS: We performed a retrospective analysis of adult patients (n = 97) with primary head and neck sarcomas treated between 2000 and 2012. We analyzed the treatment, outcome, and potential factors predictive of disease-free survival and disease-specific survival...
December 2014: Otolaryngology—Head and Neck Surgery
https://www.readbyqxmd.com/read/23372919/systemic-therapy-in-primary-angiosarcoma-of-the-spleen
#3
Bruna Pellini Ferreira, Eve T Rodler, Elizabeth T Loggers, Seth M Pollack, Robin L Jones
Primary splenic angiosarcoma is a very rare neoplasm with a high propensity for metastatic disease and poor prognosis. There is a paucity of literature concerning this specific sarcoma subtype and the role of systemic therapy is not well defined. A retrospective review of the prospectively maintained University of Washington/Seattle Cancer Care Alliance Sarcoma Unit database was performed to identify patients with splenic angiosarcoma treated between 2007 and 2012. In total there were 19 patients with angiosarcoma treated at the Seattle Cancer Care Alliance from 2007 to 2012...
October 10, 2012: Rare Tumors
https://www.readbyqxmd.com/read/22384167/nyeso-1-lage-1s-and-prame-are-targets-for-antigen-specific-t-cells-in-chondrosarcoma-following-treatment-with-5-aza-2-deoxycitabine
#4
Seth M Pollack, Yonqing Li, Megan J Blaisdell, Erik A Farrar, Jeffrey Chou, Benjamin L Hoch, Elizabeth T Loggers, Eve Rodler, Janet F Eary, Ernest U Conrad, Robin L Jones, Cassian Yee
BACKGROUND: Chondrosarcoma has no proven systemic option in the metastatic setting. The development of a non-cross-resistant strategy, such as cellular immunotherapy using antigen-specific T cells would be highly desirable. NY-ESO-1 and PRAME are members of the Cancer Testis Antigen (CTA) family that have been identified as promising targets for T cell therapy. LAGE-1 is a cancer testis antigen 90% homologous to NY-ESO-1, sharing the 157-165 A*0201 NY-ESO-1 epitope with its transcript variant, LAGE-1s...
2012: PloS One
https://www.readbyqxmd.com/read/22359263/ny-eso-1-is-a-ubiquitous-immunotherapeutic-target-antigen-for-patients-with-myxoid-round-cell-liposarcoma
#5
Seth M Pollack, Achim A Jungbluth, Benjamin L Hoch, Erik A Farrar, Marie Bleakley, David J Schneider, Elizabeth T Loggers, Eve Rodler, Janet F Eary, Ernest U Conrad, Robin L Jones, Cassian Yee
BACKGROUND: Myxoid/round cell liposarcoma (MRCL) is the second most common liposarcoma subtype, accounting for >33% of liposarcomas and approximately 10% of all soft tissue sarcomas. Although MRCL is a chemosensitive subtype, patients with metastatic disease have a poor outcome. NY-ESO-1 is a cancer-testis antigen (also known as cancer germ cell antigen) that has been successfully targeted in vaccine trials and in adoptive T-cell therapy trials for the treatment of several solid tumors...
September 15, 2012: Cancer
https://www.readbyqxmd.com/read/10761747/is-%C3%A3-ne-cycle-every-three-or-four-weeks-obsolete-a-critical-review-of-dose-dense-chemotherapy-in-solid-neoplasms
#6
REVIEW
K Fizazi, L Zelek
BACKGROUND: Shortening the interval between cycles is one means of increasing the dose intensity of chemotherapy, and can be supported by biological and mathematical rationales. Our objective was to assess the clinical relevance of the rapid repetition of regimens (so-called 'dose-dense chemotherapy') in various solid neoplasms. DESIGN: The medical literature was reviewed in accord with Mulrow's recommendations. Randomised studies comparing frequently-repeated chemotherapy to standard regimens as well as open studies are described and critically examined...
February 2000: Annals of Oncology: Official Journal of the European Society for Medical Oncology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"